

## IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market

IRLAB Therapeutics AB ("IRLAB" or the "Company") (IRLAB is currently listed on Nasdaq First North Premier Growth Market under the ticker IRLAB A) announced on September 23, 2020, that Nasdaq Stockholm's listing committee had approved IRLAB's application for admission to trading of the Company's shares of series A on Nasdaq Stockholm Main Market. Today, on September 25, 2020, the prospectus that has been prepared by the Company in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority ("SFSA") and is now available on IRLAB's website, [www.irlab.se](http://www.irlab.se) and on SFSA's website, [www.fi.se](http://www.fi.se).

The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020, and the last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September 29, 2020.

No new shares will be issued in connection with the list change and the shareholders in IRLAB do not need to take any measures in connection with the list change.

### Advisor

MAQS Advokatbyrå is the Company's legal advisor in connection with the listing on Nasdaq Stockholm.

### For more information

Nicholas Waters, CEO  
Tel: +46 730 75 77 01  
E-post: [nicholas.waters@irlab.se](mailto:nicholas.waters@irlab.se)

Viktor Siewertz, CFO  
Tel: +46 727 10 70 70  
E-post: [viktor.siewertz@irlab.se](mailto:viktor.siewertz@irlab.se)

### About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North Premier Growth Market is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se), +46 (0)8528 00 399. More information on [www.irlab.se](http://www.irlab.se).